FGFR1 and FGF9

Data Source:
HPRD (in vivo, in vitro)

		FGFR1	FGF9
Description		fibroblast growth factor receptor 1	fibroblast growth factor 9
Image
GO Annotations	Cellular Component	Extracellular Region Nucleus Cytosol Plasma Membrane Integral Component Of Plasma Membrane Integral Component Of Membrane Cytoplasmic Vesicle Receptor Complex	Extracellular Region Basement Membrane Extracellular Space Cytoplasm
	Molecular Function	Protein Tyrosine Kinase Activity Transmembrane Receptor Protein Tyrosine Kinase Activity Fibroblast Growth Factor-activated Receptor Activity Protein Binding ATP Binding Heparin Binding Fibroblast Growth Factor Binding Identical Protein Binding Protein Homodimerization Activity Receptor-receptor Interaction	Fibroblast Growth Factor Receptor Binding Growth Factor Activity Heparin Binding
	Biological Process	MAPK Cascade Skeletal System Development Neuron Migration Epithelial To Mesenchymal Transition Protein Phosphorylation Transmembrane Receptor Protein Tyrosine Kinase Signaling Pathway Multicellular Organism Development Positive Regulation Of Cell Population Proliferation Fibroblast Growth Factor Receptor Signaling Pathway Positive Regulation Of Phospholipase Activity Positive Regulation Of Phospholipase C Activity Positive Regulation Of Phosphatidylinositol 3-kinase Signaling Cell Migration Peptidyl-tyrosine Phosphorylation Positive Regulation Of Kinase Activity Chordate Embryonic Development Positive Regulation Of MAP Kinase Activity Positive Regulation Of MAPK Cascade Positive Regulation Of Blood Vessel Endothelial Cell Migration Regulation Of Cell Differentiation Positive Regulation Of Cell Differentiation Positive Regulation Of Neuron Differentiation Protein Autophosphorylation Phosphatidylinositol-mediated Signaling Skeletal System Morphogenesis Positive Regulation Of Protein Kinase B Signaling Positive Regulation Of Vascular Endothelial Cell Proliferation Positive Regulation Of Endothelial Cell Chemotaxis To Fibroblast Growth Factor Regulation Of Extrinsic Apoptotic Signaling Pathway In Absence Of Ligand	MAPK Cascade Positive Regulation Of Protein Phosphorylation Signal Transduction Cell-cell Signaling Positive Regulation Of Cell Population Proliferation Fibroblast Growth Factor Receptor Signaling Pathway Male Gonad Development Animal Organ Morphogenesis Positive Regulation Of Gene Expression Substantia Nigra Development Cell Differentiation Lung Development Regulation Of Cell Migration Positive Regulation Of MAPK Cascade Positive Regulation Of Epithelial Cell Proliferation Positive Regulation Of Cell Division Positive Regulation Of Protein Kinase B Signaling Positive Regulation Of Vascular Associated Smooth Muscle Cell Proliferation Positive Regulation Of Vascular Associated Smooth Muscle Cell Migration Negative Regulation Of Vascular Associated Smooth Muscle Cell Differentiation Involved In Phenotypic Switching
Pathways		Signaling by activated point mutants of FGFR1 Signaling by FGFR1 in disease Signaling by plasma membrane FGFR1 fusions	PI3K Cascade PIP3 activates AKT signaling Signaling by activated point mutants of FGFR1 Signaling by activated point mutants of FGFR3 FGFR4 ligand binding and activation FGFR3b ligand binding and activation FGFR3c ligand binding and activation FGFR1c ligand binding and activation FGFR2c ligand binding and activation FGFR3 mutant receptor activation Activated point mutants of FGFR2 Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade: FGFR1 Phospholipase C-mediated cascade; FGFR2 Phospholipase C-mediated cascade; FGFR3 Phospholipase C-mediated cascade; FGFR4 Downstream signaling of activated FGFR1 SHC-mediated cascade:FGFR1 PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Signaling by FGFR2 in disease Signaling by FGFR1 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Signaling by FGFR3 point mutants in cancer Transcriptional regulation of testis differentiation
Drugs		Palifermin Sorafenib Heparin 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone XL999 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine (E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE Regorafenib Ponatinib Lenvatinib Nintedanib Fostamatinib Erdafitinib Pemigatinib Selpercatinib Pralsetinib
Diseases		Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate Hypogonadotropic hypogonadism; Kallmann syndrome (KAL) Osteoglophonic dysplasia (OD); Osteoglophonic dwarfism (OGD) Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
GWAS		Adult body size ( 32376654) anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy) ( 31835028) Autism spectrum disorder or schizophrenia ( 28540026) Bipolar disorder ( 31043756) Birth weight ( 31043758) Body size at age 10 ( 32376654) Electrocardiogram morphology (amplitude at temporal datapoints) ( 32916098) Erosive tooth wear (severe vs non-severe) ( 29898447) Erosive tooth wear (severe vs none or mild) ( 29898447) Nonsyndromic cleft lip with cleft palate ( 28232668) PR interval ( 30046033 32439900) Response to cognitive-behavioural therapy in anxiety disorder ( 26989097) Schizophrenia ( 29483656) Triglyceride levels ( 32203549) Type 2 diabetes ( 32499647)	Amyotrophic lateral sclerosis (sporadic) ( 24529757) Asthma (childhood onset) ( 27611488) Central corneal thickness ( 29760442) Chin dimples ( 27182965) Corneal structure ( 23291589) Medication use (agents acting on the renin-angiotensin system) ( 31015401) Medication use (calcium channel blockers) ( 31015401) Medication use (diuretics) ( 31015401) Modified Stumvoll Insulin Sensitivity Index (BMI interaction) ( 27416945) Systolic blood pressure ( 30224653) Type 2 diabetes ( 32499647)
Interacting Genes		67 interacting genes: BNIP2 CDH1 CREBBP CRK CTPS2 EPHA4 ERBB2 ERBB3 FBXO7 FDPS FGF1 FGF10 FGF17 FGF18 FGF2 FGF3 FGF4 FGF5 FGF6 FGF7 FGF8 FGF9 FLRT3 FRS2 FRS3 GRB14 GRB2 HTR1A HULC IL17RD ITGB3 ITK KLB KPNB1 L1CAM LDHA MFHAS1 MMP2 NCAM1 NCK1 NCK2 NECTIN1 NEDD4 NRP1 PDGFRB PDK1 PDP1 PIK3R1 PIK3R2 PKM PLCG1 PTK6 PTPN1 RARA RASA1 RPS6KA1 RPS6KA3 RTN1 RTN3 SH3BP2 SHC1 SLA SOS1 TNK2 TNS2 VAV1 YES1	4 interacting genes: FGFR1 FGFR2 FGFR3 FGFR4
Entrez ID		2260	2254
HPRD ID		00634	02951
Ensembl ID		ENSG00000077782	ENSG00000102678
Uniprot IDs		A0A0S2Z3Q6 A0A3B3ISD1 P11362	P31371
PDB IDs		1AGW 1CVS 1EVT 1FGI 1FGK 1FQ9 1XR0 2CR3 2FGI 3C4F 3DPK 3GQI 3GQL 3JS2 3KRJ 3KRL 3KXX 3KY2 3OJV 3RHX 3TT0 4F63 4F64 4F65 4NK9 4NKA 4NKS 4RWI 4RWJ 4RWK 4RWL 4UWB 4UWC 4UWY 4V01 4V04 4V05 4WUN 4ZSA 5A46 5A4C 5AM6 5AM7 5B7V 5EW8 5FLF 5O49 5O4A 5UQ0 5UR1 5VND 5W21 5W59 5Z0S 5ZV2 6C18 6C19 6C1B 6C1C 6C1O 6ITJ 6MZQ 6MZW 6NVL 6P68 6P69	1G82 1IHK 5W59
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?